A Phase 2 interventional study of Alirocumab and Cemiplimab in Non-small Cell Lung Cancer (NSCLC), sponsored by Duke University. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Duke University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 19 open to participants now, 23 under way, 4 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.
Among the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 3 that started in 2023, is one of 19 in phase 2, reaches primary completion later than 1 of the 22 other live ones, and was the 8th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →19 of the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Georgetown University · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
UNICANCER · Sites in France
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Austria, Estonia, France and 6 more countries
Ages 18+
Maia Biotechnology · Sites in Poland, Romania, Taiwan and 1 more country
Ages 18+
By country, each count listing its studies:
cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 7
First in 2017; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 62 across the 30 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 30 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
21 studies in Carcinoma, Non-Small-Cell Lung by Duke University: 2 open now, 3 under way, none of them phase 3. Of 17 finished, 10 (59%) have results posted.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Duke University, this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 in phase 2, and was the 19th registered.
Duke University’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1997.
3 of the studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06908304Phase 3Maia BiotechnologyA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | 2027-07-31 |
| NCT06088771Icahn School of Medicine at Mount SinaiNeoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | 2026-12-01 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Duke University’s 21 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination of anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab
Combination Product: Alirocumab and Cemiplimab
Drug pages: AlirocumabStudies of AlirocumabAlirocumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CemiplimabStudies of CemiplimabCemiplimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks
Number of Participants With a Complete or Partial Response (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 Criteria
A partial response (PR) under RECIST 1.1 guidelines indicates there is at least a 30% decrease in the sum of the longest diameters of target tumors, compared to the baseline measurement.
Time frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks per RECIST 1.1
Number of Participants Who Experienced an Adverse Event
A measurement of the safety and tolerability of the combination regimen. Toxicity analysis will be performed on a continual basis following CTC V 5.0 criteria.
Time frame: Day 1 of treatment until 30 days post last day of treatment for up to 2 years of treatment duration or when patient comes off treatment earlier than 2 years due to any other reason
Progression Free Survival (PFS) Per RECIST 1.1. Criteria
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or unequivocal progression of non-target lesion(s), or the appearance of new lesion(s), or death
Time frame: Day 1 of treatment until the date of first documented progression or date of death, whichever comes first, assessed up to 110 weeks
Overall Survival (OS)
Overall survival (OS) is the length of time that participants remain alive.
Time frame: Day 1 of treatment until death or off study due to any other reason whichever comes first, assessed up to 110 weeks
| Milestone | Experimental: Alirocumab and Cemiplimab |
|---|---|
| Started | 60 |
| Completed | 60 |
| Not completed | 0 |
A partial response (PR) under RECIST 1.1 guidelines indicates there is at least a 30% decrease in the sum of the longest diameters of target tumors, compared to the baseline measurement.
| Participants | Experimental: Alirocumab and Cemiplimab |
|---|---|
| Number of Participants With a Complete or Partial Response (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 Criteria | 5 |
A measurement of the safety and tolerability of the combination regimen. Toxicity analysis will be performed on a continual basis following CTC V 5.0 criteria.
| Participants | Experimental: Alirocumab and Cemiplimab |
|---|---|
| Number of Participants Who Experienced an Adverse Event | 56 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or unequivocal progression of non-target lesion(s), or the appearance of new lesion(s), or death
| months | Experimental: Alirocumab and Cemiplimab |
|---|---|
| Progression Free Survival (PFS) Per RECIST 1.1. Criteria | 2.52 (1.5 to 3.0) |
Overall survival (OS) is the length of time that participants remain alive.
| months | Experimental: Alirocumab and Cemiplimab |
|---|---|
| Overall Survival (OS) | 7.04 (5.25 to 11.64) |
Collected over Day 1 of treatment until 30 days post last day of treatment for up to 2 years of treatment duration or when patient comes off treatment earlier than 2 years due to any other reason. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Alirocumab and Cemiplimab | 48/60 (80%) | 29/60 (48.3%) | 56/60 (93.3%) |
| Event | Experimental: Alirocumab and Cemiplimab |
|---|---|
| Nervous system disorders - Other, specifyNervous system disorders | 3/60 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/60 |
| HypotensionVascular disorders | 3/60 |
| Atrial fibrillationCardiac disorders | 2/60 |
| Sinus tachycardiaCardiac disorders | 2/60 |
| Adrenal insufficiencyEndocrine disorders | 2/60 |
| General disorders and administration site conditions - Other, specifyGeneral disorders | 2/60 |
| PainGeneral disorders | 2/60 |
| FractureInjury, poisoning and procedural complications | 2/60 |
| Spinal fractureInjury, poisoning and procedural complications | 2/60 |
| Event | Experimental: Alirocumab and Cemiplimab |
|---|---|
| AnemiaBlood and lymphatic system disorders | 24/60 |
| HypoalbuminemiaMetabolism and nutrition disorders | 22/60 |
| HyponatremiaMetabolism and nutrition disorders | 19/60 |
| FatigueGeneral disorders | 15/60 |
| Alkaline phosphatase increasedInvestigations | 14/60 |
| HyperglycemiaMetabolism and nutrition disorders | 14/60 |
| HypocalcemiaMetabolism and nutrition disorders | 14/60 |
| NauseaGastrointestinal disorders | 13/60 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/60 |
| Investigations - Other, specifyInvestigations | 11/60 |
| Age, Categorical(Participants) | Alirocumab and Cemiplimab |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 16 |
| >=65 years | 44 |
| Age, Continuous(years) | Alirocumab and Cemiplimab |
|---|---|
| Mean | 68.6 ± 7.96 |
| Sex: Female, Male(Participants) | Alirocumab and Cemiplimab |
|---|---|
| Female | 28 |
| Male | 32 |
| Ethnicity (NIH/OMB)(Participants) | Alirocumab and Cemiplimab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 58 |
| Unknown or Not Reported | 2 |
| Race/Ethnicity, Customized(Participants) | Alirocumab and Cemiplimab |
|---|---|
| Black or African American | 12 |
| White | 44 |
| Unknown or Not Reported | 4 |
| Region of Enrollment(Participants) | Alirocumab and Cemiplimab |
|---|---|
| United States | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2023 to primary completion in Sep 2025, 28 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 28 months is below that.
Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alirocumab · Cemiplimab
Carcinoma, Non-Small-Cell Lung →